Methods and compositions for treating Huntington's disease
Disclosed herein are compositions comprising non-naturally occurring zinc finger domains, fusion proteins comprising these zinc finger domains, polynucleotides encoding these proteins, cells expressing these proteins and pharmaceutical compositions comprising these proteins or polynucleotides as well as methods of modifying an Htt gene using these compositions for treating or preventing Huntington's Disease.
1. An mRNA encoding a fusion protein comprising a transcriptional repression domain and a non-naturally occurring zinc finger protein comprising 6 zinc finger domains ordered F1 to F6, respectively, wherein the zinc finger protein specifically binds to mutant Huntington's gene allele (mHtt) gene and comprises the recognition helix regions as follows:
(SEQ ID NO: 60)
F1: RSDNLSE;
(SEQ ID NO: 61)
F2: KRCNLRC;
(SEQ ID NO: 18)
F3: QSGDLTR;
(SEQ ID NO: 18)
F4: QSGDLTR;
(SEQ ID NO: 60)
F5: RSDNLSE;
and
(SEQ ID NO: 61)
F6: KRCNLRC.
2. The mRNA of claim 1 , wherein the zinc finger protein binds to sequences within the CAG repeat region of the mHtt gene.
3. A host cell comprising one or more mRNAs of claim 1 .
4. A method of modifying expression of an mHtt gene in a cell, the method comprising administering to the cell one or more polynucleotides encoding one or more mRNAs according to claim 1 .
5. A method of treating Huntington's Disease, the method comprising administering one or more mRNAs according to claim 1 to a subject in need thereof.
6. A pharmaceutical composition comprising one or more mRNAs according to claim 1 .
7. A method of treating Huntington's Disease, the method comprising administering the pharmaceutical composition according to claim 6 to a subject in need thereof.